Advanced Nonhematologic Malignancies
9
0
0
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 35/100
11.1%
1 terminated out of 9 trials
87.5%
+1.0% vs benchmark
0%
0 trials in Phase 3/4
71%
5 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (9)
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
Study of MLN4924 in Adult Patients With Nonhematologic Malignancies
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies